{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:43:01Z","timestamp":1792672981654,"version":"4.5.0"},"reference-count":61,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec id=\"ab-noi260041-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Myelin oligodendrocyte glycoprotein antibody\u2013associated disease (MOGAD) lacks proven relapse-preventive therapies. While clinical trials are ongoing, safety data may be limited and approved drugs are costly. Studies of interleukin 6 receptor blocker (IL-6RB) in MOGAD are limited by small numbers and no comparative studies, contributing to low use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi260041-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the impact of IL-6RB therapy on relapse rates in MOGAD and compare relapse frequency with intravenous immunoglobulin (IVIG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi260041-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This international, multicenter, retrospective cohort study (January 1, 2015, through December 31, 2025) included a historical IVIG-treated cohort of varying doses. The study took place across sites in North and South America (US, Canada, Mexico, Argentina, Brazil, Chile, Colombia, and Peru). Patients with MOGAD (n\u2009=\u2009116, no excluded patients) who received at least 1 dose of an IL-6RB were included. These data were analyzed in January 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi260041-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Tocilizumab or satralizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi260041-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Annualized relapse rate (ARR) during IL-6RB therapy, time to next relapse after treatment initiation, and adverse events. Outcomes were compared with the IVIG cohort using inverse probability of treatment weighting (IPTW) adjusted for age, sex, prior ARR, and concomitant therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi260041-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 116 patients with MOGAD (89% relapsing) receiving IL-6RB (tocilizumab, 104 [90%] and satralizumab, 12 [10%]) were included; overall, 60.3% were female, 39.7% were male, and 18% were younger than 18 years. The median (IQR) IL-6RB treatment follow-up was 1.4 (0.7-2.5) years and 23 relapses occurred during 241.8 person-years of IL-6RB therapy. The ARR decreased from 0.64 (95% CI, 0.58-0.70) for relapsing MOGAD before IL-6RB to 0.09 (95% CI, 0.06-0.14) during IL-6RB treatment (incidence rate ratio, 0.08; 95% CI, 0.04-0.16). Adverse events occurred in 58 patients (50%), most commonly mild infections, although 10 (9%) had severe infections. In the IVIG cohort (n\u2009=\u200959), 30 relapses occurred over 133.8 person-years (ARR, 0.22; 95% CI, 0.15-0.32). After IPTW, IL-6RB was associated with a lower hazard ratio (HR) than the group who underwent IVIG therapy less than 1 g\/kg every 4 weeks (HR, 4.5; 95% CI, 2.0-9.8), with no significant difference vs the group who underwent IVIG 1 g\/kg or more every 4 weeks (HR, 2.0; 95% CI, 0.8-4.5).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi260041-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this multicenter observational cohort, IL-6RB use in MOGAD was associated with low relapse rates and a favorable safety profile, though severe infections occurred occasionally. Relapse rates were lower than the group who underwent IVIG less than 1 g\/kg every 4 weeks but not significantly different from the group who underwent IVIG 1 g\/kg or more every 4 weeks. This supports IL-6RB as a potential relapse-prevention therapy in MOGAD; the wide availability and relative affordability of tocilizumab may enable broad global use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaneurol.2026.2220","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:00:19Z","timestamp":1783954819000},"page":"860","source":"Crossref","is-referenced-by-count":5,"title":["Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody\u2013Associated Disease"],"prefix":"10.1001","volume":"83","author":[{"given":"Andreu","family":"Vilaseca","sequence":"first","affiliation":[{"name":"Department of Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe A.","family":"Bilodeau","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Gakis","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Savransky","sequence":"additional","affiliation":[{"name":"Paediatric Neuroimmunology Clinic, Department of Neurology, National Paediatric Hospital Dr J P Garrahan, Ciudad de Buenos Aires, Argentina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Mahler Ferreira Oliveira","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam I.","family":"Hooshmand","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammita","family":"Satyanarayan","sequence":"additional","affiliation":[{"name":"Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carson E.","family":"Moseley","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco"},{"name":"Program in Immunology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Haley","sequence":"additional","affiliation":[{"name":"Department of Neurology, New York University Langone Medical Centre, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Roy-Hewitson","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences, Larner College of Medicine at the University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Marrodan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fleni, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Casallas","sequence":"additional","affiliation":[{"name":"Cayre Multiple Sclerosis Center, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Analisa","family":"Manin","sequence":"additional","affiliation":[{"name":"Centro Argentino de Neuroinmunolog\u00eda (CADENI), Hospital General de Agudos Jos\u00e9 Mar\u00eda Ramos Mej\u00eda, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Hoshina","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniela","family":"Grzezulkowska","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Carnero Contentti","sequence":"additional","affiliation":[{"name":"Neuroimmunology Unit, Department of Neurosciences, Hospital Aleman, Buenos Aires, Argentina; CENRos, Neuroimmunology Clinic, INECO Neurociencias Oro\u00f1o, Rosario, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Galleguillos","sequence":"additional","affiliation":[{"name":"Neuroimmunology Unit, Department of Neurology and Psychiatry, Clinica Alemana of Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Upchurch","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado Anschutz School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin S.","family":"Jackson-Tarlton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Neurology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Chu-Yueh Guo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fabian","sequence":"additional","affiliation":[{"name":"Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Virupakshaiah","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Arrambide","sequence":"additional","affiliation":[{"name":"Neurology-Neuroimmunology Department, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d\u2019Hebron Barcelona Hospital Campus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Capar\u00f3-Zamalloa","sequence":"additional","affiliation":[{"name":"Centro B\u00e1sico de Investigaci\u00f3n en Demencia y enfermedades desmielinizantes del SNC, Instituto Nacional de Ciencias Neurol\u00f3gicas, Lima, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Paterno","sequence":"additional","affiliation":[{"name":"Irmandade da Santa Casa de S\u00e3o Paulo, Servi\u00e7o de Neurologia, S\u00e3o Paulo SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Waubant","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ordo\u00f1ez Boschetti","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Espa\u00f1ol de Mexico, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Correale","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fleni, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres M.","family":"Villa","sequence":"additional","affiliation":[{"name":"Centro Argentino de Neuroinmunolog\u00eda (CADENI), Hospital General de Agudos Jos\u00e9 Mar\u00eda Ramos Mej\u00eda, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Banwell","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Marignier","sequence":"additional","affiliation":[{"name":"Service de neurologie, scl\u00e9rose en plaques, pathologies de la my\u00e9line et neuro-inflammation, and Centre de R\u00e9f\u00e9rence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, H\u00f4pital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France; Centre de Recherche en Neurosciences de Lyon, Lyon, France; Universit\u00e9 Claude Bernard Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota"},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado Anschutz School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Clardy","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences, Larner College of Medicine at the University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Kister","sequence":"additional","affiliation":[{"name":"Department of Neurology, New York University Langone Medical Centre, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott S.","family":"Zamvil","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco"},{"name":"Program in Immunology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Gelfand","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavle","family":"Repovic","sequence":"additional","affiliation":[{"name":"Department of Neurology, Swedish Medical Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Z.","family":"Obeidat","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Blackburn","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Tenembaum","sequence":"additional","affiliation":[{"name":"Paediatric Neuroimmunology Clinic, Department of Neurology, National Paediatric Hospital Dr J P Garrahan, Ciudad de Buenos Aires, Argentina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota"},{"name":"Department of Ophthalmology, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias S.","family":"Sotirchos","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P.","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota"},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and The Americas MOGAD Treatment Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Murillo","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie B.","family":"Syc-Mazurzek","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota"},{"name":"Neurology-Neuroimmunology Department, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d\u2019Hebron Barcelona Hospital Campus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cacciaguerra","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathane Braga","family":"da Silva Rezende","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (Clinical Medicine), School of Medicine, Universidad de Est\u00e1cio de S\u00e1, Rio de Janeiro, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean M","family":"Wingerchuk","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Horsman","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"noi260041r1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"issue":"10","key":"noi260041r2","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK.","volume":"91","author":"O\u2019Connell","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"noi260041r3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s00415-024-12861-9","article-title":"MOG antibody-associated disease epidemiology in Olmsted County, USA, and Martinique.","volume":"272","author":"Cacciaguerra","year":"2025","journal-title":"J Neurol"},{"key":"noi260041r4","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200275","article-title":"MOG CNS autoimmunity and MOGAD.","author":"Moseley","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"noi260041r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103693","article-title":"MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally.","volume":"24","author":"Trewin","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"4","key":"noi260041r6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ana.26858","article-title":"Time to disability milestones and annualized relapse rates in NMOSD and MOGAD.","volume":"95","author":"Duchow","year":"2024","journal-title":"Ann Neurol"},{"issue":"12","key":"noi260041r7","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder.","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol"},{"issue":"5","key":"noi260041r8","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/ene.14746","article-title":"The long-term outcome of MOGAD: an observational national cohort study of 61 patients.","volume":"28","author":"Deschamps","year":"2021","journal-title":"Eur J Neurol"},{"issue":"10","key":"noi260041r9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1136\/jnnp-2022-330901","article-title":"Clinical feature and disease outcome in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder: a Chinese study.","volume":"94","author":"ZhangBao","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"noi260041r10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis.","volume":"77","author":"Pr\u00f6bstel","year":"2011","journal-title":"Neurology"},{"key":"noi260041r11","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000081","article-title":"Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children.","author":"Hacohen","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"noi260041r12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209624","article-title":"Early maintenance treatment initiation and relapse risk mitigation after a first event of MOGAD in adults: the MOGADOR2 study.","volume":"103","author":"Deschamps","year":"2024","journal-title":"Neurology"},{"issue":"4","key":"noi260041r13","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"key":"noi260041r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577812","article-title":"Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): a systematic review and meta-analysis.","volume":"364","author":"Nepal","year":"2022","journal-title":"J Neuroimmunol"},{"issue":"22","key":"noi260041r15","doi-asserted-by":"publisher","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease.","volume":"99","author":"Barreras","year":"2022","journal-title":"Neurology"},{"key":"noi260041r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients.","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"noi260041r17","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease.","volume":"79","author":"Chen","year":"2022","journal-title":"JAMA Neurol"},{"issue":"3","key":"noi260041r18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/13524585241226830","article-title":"Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.","volume":"30","author":"Bilodeau","year":"2024","journal-title":"Mult Scler"},{"issue":"2","key":"noi260041r19","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder.","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"key":"noi260041r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103462","article-title":"Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin.","volume":"57","author":"Sotirchos","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"noi260041r21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1255533","article-title":"Interleukin 6: at the interface of human health and disease.","volume":"14","author":"Grebenciucova","year":"2023","journal-title":"Front Immunol"},{"issue":"8","key":"noi260041r22","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1177\/13524585241254731","article-title":"Contributions of CSF interleukin-6 elevation to the pathogenesis of myelin oligodendrocyte glycoprotein antibody-associated disease.","volume":"30","author":"Uzawa","year":"2024","journal-title":"Mult Scler"},{"key":"noi260041r23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.10.002","article-title":"Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis.","volume":"289","author":"Horellou","year":"2015","journal-title":"J Neuroimmunol"},{"key":"noi260041r24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1037812","article-title":"Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.","volume":"13","author":"Bauer","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"noi260041r26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"noi260041r27","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200243","article-title":"Life-threatening MOG antibody-associated hemorrhagic adem with elevated CSF IL-6.","author":"Virupakshaiah","year":"2024","journal-title":"Neurology"},{"key":"noi260041r28","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200150","article-title":"Dramatic response to anti-IL-6 receptor therapy in children with life-threatening myelin oligodendrocyte glycoprotein-associated disease.","author":"McLendon","year":"2023","journal-title":"Neurology"},{"issue":"8","key":"noi260041r29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214926","article-title":"Role of tocilizumab in severe CNS inflammatory presentations in children.","volume":"106","author":"Marefi","year":"2026","journal-title":"Neurology"},{"issue":"2","key":"noi260041r30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/13524585251396421","article-title":"Place of anti-IL6R in the therapeutic strategy in NMOSD-AQP4+, MOGAD, and NMOSD double-seronegative patients.","volume":"32","author":"Comet","year":"2026","journal-title":"Mult Scler"},{"key":"noi260041r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102483","article-title":"Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: a case-series.","volume":"46","author":"Rigal","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"16","key":"noi260041r32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1212\/WNL.0000000000007312","article-title":"Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis.","volume":"92","author":"Hayward-Koennecke","year":"2019","journal-title":"Neurology"},{"key":"noi260041r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102696","article-title":"Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review.","volume":"48","author":"Elsbernd","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"noi260041r34","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241306685","article-title":"Efficacy and safety of tocilizumab treatment in refractory MOG-IgG related optic neuritis.","volume":"17","author":"Xu","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"noi260041r35","doi-asserted-by":"publisher","first-page":"877","DOI":"10.4103\/aian.aian_399_25","article-title":"Tocilizumab in refractory neuro myelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease\u2014experience from a tertiary care centre.","volume":"28","author":"Shaik","year":"2025","journal-title":"Ann Indian Acad Neurol"},{"key":"noi260041r36","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders.","author":"Ringelstein","year":"2021","journal-title":"Neurology"},{"key":"noi260041r37","doi-asserted-by":"publisher","DOI":"10.1212\/WN9.0000000000000049","article-title":"Long-term treatment with interleukin-6 receptor inhibitor tocilizumab in myelin oligodendrocyte glycoprotein antibody-associated disease.","author":"Capecchi","year":"2025","journal-title":"Neurology"},{"key":"noi260041r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105859","article-title":"Efficacy of tocilizumab in highly relapsing MOGAD with an inadequate response to intravenous immunoglobulin therapy: a case series.","volume":"91","author":"Kang","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"noi260041r39","doi-asserted-by":"publisher","DOI":"10.1212\/WN9.0000000000000063","article-title":"Anti-IL-6 Receptor blockers hold promise for relapse prevention in MOGAD?","volume":"2","author":"Vilaseca","year":"2026","journal-title":"Neurology Open Access"},{"key":"noi260041r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106460","article-title":"Latin American RAND\/UCLA modified Delphi consensus recommendations for management and treatment of adult MOGAD patients in clinical practice.","volume":"99","author":"Carnero Contentti","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"noi260041r41","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200249","article-title":"MOG antibody-associated disease in the setting of metastatic melanoma complicated by immune checkpoint inhibitor use.","author":"Syc-Mazurek","year":"2024","journal-title":"Neurology"},{"issue":"5","key":"noi260041r42","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"issue":"22","key":"noi260041r43","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder.","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"noi260041r44","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome.","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"noi260041r45","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104571","article-title":"Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease.","volume":"72","author":"Chang","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"noi260041r46","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213557","article-title":"Clinical features and factors associated with outcome in late adult-onset myelin oligodendrocyte glycoprotein antibody-associated disease.","volume":"104","author":"Dinoto","year":"2025","journal-title":"Neurology"},{"issue":"4","key":"noi260041r48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/14728214.2025.2565189","article-title":"Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape.","volume":"30","author":"Carnero Contentti","year":"2025","journal-title":"Expert Opin Emerg Drugs"},{"key":"noi260041r53","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106602","article-title":"Treatment strategies of AQP4-IgG positive neuromyelitis optica spectrum disorder and MOG antibody-associated disorder in Switzerland: a nationwide survey.","volume":"102","author":"Steinegger","year":"2025","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"noi260041r54","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis.","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"noi260041r55","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.11095","article-title":"Tocilizumab monotherapy or combined with methotrexate for rheumatoid arthritis: a randomized clinical trial.","volume":"8","author":"Liu","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"10","key":"noi260041r56","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/1759720X18798462","article-title":"New insights and long-term safety of tocilizumab in rheumatoid arthritis.","volume":"10","author":"Jones","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"noi260041r57","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1476213","article-title":"Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China.","volume":"12","author":"Du","year":"2024","journal-title":"Front Public Health"},{"issue":"4","key":"noi260041r58","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3969","article-title":"Assessment of expected out-of-pocket spending for rheumatoid arthritis biologics among patients enrolled in Medicare part D, 2010-2019.","volume":"3","author":"Erath","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"11","key":"noi260041r59","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.42937","article-title":"Biologic drug prices in Medicare part B after entry of biosimilars to the market.","volume":"8","author":"Abdelaziz","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"9","key":"noi260041r60","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"key":"noi260041r61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577467","article-title":"Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders.","volume":"351","author":"Akaishi","year":"2021","journal-title":"J Neuroimmunol"},{"key":"noi260041r25","article-title":"Profile and usefulness of serum cytokines to predict prognosis in myelin oligodendrocyte glycoprotein antibody-associated disease.","volume-title":"Neurology","author":"Villacieros-\u00c1lvarez","year":"2025"},{"key":"noi260041r47","unstructured":"European Medicines Agency. RoActemra (tocilizumab). Accessed June 11, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_en.pdf"},{"key":"noi260041r49","unstructured":"ClinicalTrials.org. A study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with myelin oligodendrocyte glycoprotein antibody-associated disease (METEOROID). Accessed June 11, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05271409"},{"key":"noi260041r50","unstructured":"ClinicalTrials.org. A study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with myelin oligodendrocyte glycoprotein antibody-associated disease (METEOROID). Accessed June 11, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05271409"},{"key":"noi260041r51","unstructured":"ClinicalTrials.org. A study to evaluate the efficacy and safety of rozanolixizumab in adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) (cosMOG). Accessed June 11, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05063162"},{"key":"noi260041r52","unstructured":"Australian New Zealand Clinical Trials Registry. STAR-MOG: A phase III randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of treatment with corticoSTeroids at onset, and rituximab during a relapse, of myelin oligodendrocyte glycoprotein antibody-associated disease. Accessed June 11, 2026. https:\/\/clin.larvol.com\/trial-detail\/ACTRN12624001258549"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2851426\/jamaneurology_vilaseca_2026_oi_260041_1789047968.1628.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:02:49Z","timestamp":1789398169000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2851426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2026.2220","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}